Karma Biotechnologies is developing the first “Xavine” - a vaccine-like treatment to prevent the unhealthy immune system activity exhibited in autoimmune disorders. The founders are well-established scientists in immunology and chemical biology, bringing a good mix of in-depth scientific knowledge and creative biochemical engineering talent to the enterprise.